Verastem, Inc. (VSTM)

11,84 +0,94 (+8,62%) Börsenschluss: 04:00PM EDT

Verastem, Inc.

117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
https://www.verastem.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 73

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Daniel W. Paterson	President, CEO & Director	897,59k	N/A	1961
Mr. Daniel Calkins	CFO and Principal Accounting & Financial Officer	401,83k	N/A	1988
Mr. Richard H. Aldrich M.B.A.	Founder and Consultant	38,39k	N/A	1954
Dr. Robert A. Weinberg Ph.D.	Co-Founder & Chair of Scientific Advisory Board	N/A	N/A	N/A
Dr. Piyush B. Gupta Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Michelle Dipp M.D., Ph.D.	Co-Founder	N/A	N/A	1976
Dr. Jonathan Pachter Ph.D.	Chief Scientific Officer	238,18k	N/A	1958
Mr. Nate Sanburn	Senior Vice President of Corporate Development & External Engagement	N/A	N/A	N/A
Ms. Cathy Carew	Chief Organizational Effectiveness Officer	N/A	N/A	N/A
Mr. Michael Crowther	Chief Commercial & Business Strategy Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Corporate Governance

Verastem, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 8, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.